Regeneron Pharmaceuticals Reports on Shareholder Vote Matters
Ticker: REGN · Form: 8-K · Filed: Jun 18, 2025 · CIK: 872589
| Field | Detail |
|---|---|
| Company | Regeneron Pharmaceuticals, Inc. (REGN) |
| Form Type | 8-K |
| Filed Date | Jun 18, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: REGN
TL;DR
REGN filed an 8-K for a shareholder vote on June 13th.
AI Summary
Regeneron Pharmaceuticals, Inc. filed an 8-K on June 18, 2025, reporting on matters submitted to a vote of security holders on June 13, 2025. The filing details the company's corporate structure and its principal executive offices located at 777 Old Saw Mill River Road, Tarrytown, New York.
Why It Matters
This filing indicates a formal process of shareholder engagement and voting on corporate matters, which is a standard but important aspect of corporate governance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not introduce new financial or operational risks.
Key Players & Entities
- REGENERON PHARMACEUTICALS, INC. (company) — Registrant
- June 18, 2025 (date) — Date of Report
- June 13, 2025 (date) — Date of earliest event reported
- 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (location) — Principal executive offices
FAQ
What specific matters were submitted to a vote of Regeneron's security holders?
The filing states that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 13, 2025.
What is Regeneron Pharmaceuticals, Inc.'s principal executive office address?
The principal executive offices are located at 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707.
What is the SEC file number for Regeneron Pharmaceuticals, Inc.?
The SEC file number is 000-19034.
What is the fiscal year end for Regeneron Pharmaceuticals, Inc.?
The fiscal year end for Regeneron Pharmaceuticals, Inc. is December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 18, 2025 regarding REGENERON PHARMACEUTICALS, INC. (REGN).